Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

ALT Altimmune Inc

Price (delayed)

$4.18

Market cap

$339.03M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.26

Enterprise value

$289.88M

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), ...

Highlights
Altimmune's EPS has increased by 22% YoY and by 6% QoQ
Altimmune's net income has increased by 5% QoQ and by 2.7% YoY
ALT's quick ratio is up by 21% QoQ but it is down by 4.6% YoY
The equity has declined by 18% year-on-year but it has increased by 15% since the previous quarter
The gross profit has plunged by 96% YoY and by 25% from the previous quarter
ALT's revenue has dropped by 96% year-on-year and by 25% since the previous quarter

Key stats

What are the main financial stats of ALT
Market
Shares outstanding
81.11M
Market cap
$339.03M
Enterprise value
$289.88M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.26
Price to sales (P/S)
21,052.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19,325.41
Earnings
Revenue
$15,000
Gross profit
$15,000
Operating income
-$98.2M
Net income
-$90.24M
EBIT
-$90.91M
EBITDA
-$90.75M
Free cash flow
-$80.33M
Per share
EPS
-$1.26
EPS diluted
-$1.26
Free cash flow per share
-$1.06
Book value per share
$1.85
Revenue per share
$0
TBVPS
$2.08
Balance sheet
Total assets
$157.26M
Total liabilities
$15.1M
Debt
$0
Equity
$142.16M
Working capital
$145.46M
Liquidity
Debt to equity
0
Current ratio
15.85
Quick ratio
15.35
Net debt/EBITDA
0.54
Margins
EBITDA margin
-605,013.3%
Gross margin
100%
Net margin
-601,600%
Operating margin
-654,653.3%
Efficiency
Return on assets
-58.4%
Return on equity
-65.4%
Return on invested capital
-91.2%
Return on capital employed
-61.6%
Return on sales
-606,080%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALT stock price

How has the Altimmune stock price performed over time
Intraday
0%
1 week
-11.81%
1 month
-39.16%
1 year
-48.4%
YTD
-42.02%
QTD
8.01%

Financial performance

How have Altimmune's revenue and profit performed over time
Revenue
$15,000
Gross profit
$15,000
Operating income
-$98.2M
Net income
-$90.24M
Gross margin
100%
Net margin
-601,600%

ALT financials

The gross profit has plunged by 96% YoY and by 25% from the previous quarter
ALT's revenue has dropped by 96% year-on-year and by 25% since the previous quarter
The operating margin has declined by 27% since the previous quarter
The net margin has declined by 27% since the previous quarter

Price vs fundamentals

How does ALT's price correlate with its fundamentals

ALT Price vs fundamentals

ALT Earnings waterfall

ALT Price vs fair value

Growth

What is Altimmune's growth rate over time

ALT growth chart

Valuation

What is Altimmune stock price valuation
P/E
N/A
P/B
2.26
P/S
21,052.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19,325.41

Valuation vs average

Price to earnings (P/E)

Altimmune's EPS has increased by 22% YoY and by 6% QoQ

Price to book (P/B)

The P/B is 32% lower than the last 4 quarters average of 3.3 and 10% lower than the 5-year quarterly average of 2.5
The equity has declined by 18% year-on-year but it has increased by 15% since the previous quarter

Price to sales (P/S)

ALT's revenue has dropped by 96% year-on-year and by 25% since the previous quarter
ALT's P/S is 38% above its last 4 quarters average of 15308.3

Efficiency

How efficient is Altimmune business performance
The company's return on invested capital rose by 33% YoY and by 4.4% QoQ
Altimmune's return on sales has decreased by 28% QoQ
The return on equity has declined by 21% year-on-year
ALT's ROA is down by 18% YoY

Dividends

What is ALT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Altimmune financials performed over time

Assets vs liabilities

ALT's quick ratio is up by 21% QoQ but it is down by 4.6% YoY
Altimmune's current ratio has increased by 21% from the previous quarter but it has decreased by 4.2% YoY

Debt vs equity

The debt is 100% smaller than the equity
The equity has declined by 18% year-on-year but it has increased by 15% since the previous quarter

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.